The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Biodistribution of 89Zr-trastuzumab and PET Imaging of HER2-Positive Lesions in Patients With Metastatic Breast Cancer
Abstract
We performed a feasibility study to determine the optimal dosage and time of administration of the monoclonal antibody zirconium-89 ((89)Zr)-trastuzumab to enable positron emission tomography (PET) imaging of human epidermal growth factor receptor 2 (HER2)-positive lesions. Fourteen patients with HER2-positive metastatic breast cancer received 37 MBq of (89)Zr-trastuzumab at one of three doses (10 or 50 mg for those who were trastuzumab-naive and 10 mg for those who were already on trastuzumab treatment). The patients underwent at least two PET scans between days 2 and 5. The results of the study showed that the best time for assessment of (89)Zr-trastuzumab uptake by tumors was 4-5 days after the injection. For optimal PET-scan results, trastuzumab-naive patients required a 50 mg dose of (89)Zr-trastuzumab, and patients already on trastuzumab treatment required a 10 mg dose. The accumulation of (89)Zr-trastuzumab in lesions allowed PET imaging of most of the known lesions and some that had been undetected earlier. The relative uptake values (RUVs) (mean +/- SEM) were 12.8 +/- 5.8, 4.1 +/- 1.6, and 3.5 +/- 4.2 in liver, bone, and brain lesions, respectively, and 5.9 +/- 2.4, 2.8 +/- 0.7, 4.0 +/- 0.7, and 0.20 +/- 0.1 in normal liver, spleen, kidneys, and brain tissue, respectively. PET scanning after administration of (89)Zr-trastuzumab at appropriate doses allows visualization and quantification of uptake in HER2-positive lesions in patients with metastatic breast cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Leyland-Jones, B., Shak, S., Fuchs, H., Paton, V., Bajamonde, A., Fleming, T., Eiermann, W., Wolter, J., Pegram, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200103153441101 · Cited by 11,500
Computed Tomography — An Increasing Source of Radiation Exposure
Brenner, D. J., & Hall, E. J. (2007) · New England Journal of Medicine · doi:10.1056/nejmra072149 · Cited by 8,748
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
AMIDE: A Free Software Tool for Multimodality Medical Image Analysis
Loening, A. M., & Gambhir, S. S. (2003) · Molecular Imaging · doi:10.1162/15353500200303133 · Cited by 1,018
Baselga, J., Carbonell, X., Castañeda-Soto, N.-J., Clemens, M., Green, M., Harvey, V., Morales, S., Barton, C., & Ghahramani, P. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.014 · Cited by 425
Brain Metastases: The HER2 Paradigm
Lin, N. U., & Winer, E. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2478 · Cited by 417
Agus, D. B., Gordon, M. S., Taylor, C., Natale, R. B., Karlan, B., Mendelson, D. S., Press, M. F., Allison, D. E., Sliwkowski, M. X., Lieberman, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.184 · Cited by 390
Development and Characterization of Clinical-Grade 89Zr-Trastuzumab for HER2/neu ImmunoPET Imaging
Dijkers, E. C. F., Kosterink, J. G. W., Rademaker, A. P., Perk, L. R., van Dongen, G. A. M. S., Bart, J., de Jong, J. R., de Vries, E. G. E., & Lub-de Hooge, M. N. (2009) · Journal of Nuclear Medicine · doi:10.2967/jnumed.108.060392 · Cited by 334
Self-citationImmuno-PET: A Navigator in Monoclonal Antibody Development and Applications
van Dongen, G. A. M. S., Visser, G. W. M., Lub-de Hooge, M. N., de Vries, E. G., & Perk, L. R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-12-1379 · Cited by 330
Self-citationPerik, P. J., Lub-De Hooge, M. N., Gietema, J. A., van der Graaf, W. T. A., de Korte, M. A., Jonkman, S., Kosterink, J. G. W., van Veldhuisen, D. J., Sleijfer, D. T., Jager, P. L., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.8448 · Cited by 310
Self-citationWülfing, P., Borchard, J., Buerger, H., Heidl, S., Zänker, K. S., Kiesel, L., & Brandt, B. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2087 · Cited by 258
Population pharmacokinetics of trastuzumab in patients With HER2+ metastatic breast cancer
Bruno, R., Washington, C. B., Lu, J.-F., Lieberman, G., Banken, L., & Klein, P. (2005) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-005-1026-z · Cited by 245
de Korte, M. A., de Vries, E. G. E., Lub-de Hooge, M. N., Jager, P. L., Gietema, J. A., van der Graaf, W. T. A., Sluiter, W. J., van Veldhuisen, D. J., Suter, T. M., Sleijfer, D. T., et al. (2007) · European Journal of Cancer · doi:10.1016/j.ejca.2007.06.024 · Cited by 160
Self-citationRasbridge, S., Gillett, C. E., Seymour, A.-M., Patel, K., Richards, M., Rubens, R., & Millis, R. (1994) · British Journal of Cancer · doi:10.1038/bjc.1994.303 · Cited by 148
Solomayer, E. F., Becker, S., Becker‐Pergola, G., Bachmann, R., Krämer, B., Vogel, U. F., Neubauer, H. J., Wallwiener, D. R., Huober, J., & Fehm, T. N. (2006) · Breast Cancer Research and Treatment · doi:10.1007/s10549-005-9147-y · Cited by 122
Tokuda, Y., Watanabe, T., Omuro, Y., Ando, M., Katsumata, N., Okumura, A., Ohta, M., Fujii, H., Sasaki, Y., Niwa, T., et al. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690343 · Cited by 114
Targeting the HER-kinase axis in cancer
Gross, M. E., Shazer, R. L., & Agus, D. B. (2004) · Seminars in Oncology · doi:10.1053/j.seminoncol.2004.01.005 · Cited by 74
Beeram, M., Burris, H. A., Modi, S., Birkner, M., Girish, S., Tibbitts, J., Holden, S. N., Lutzker, S. G., & Krop, I. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.1028 · Cited by 48
Cited by
Scott, A. M., Wolchok, J. D., & Old, L. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3236 · Cited by 2,160
CNS Metastases in Breast Cancer: Old Challenge, New Frontiers
Lin, N. U., Amiri-Kordestani, L., Palmieri, D., Liewehr, D. J., & Steeg, P. S. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0790 · Cited by 1,286
Bensch, F., van der Veen, E. L., Lub-de Hooge, M. N., Jorritsma-Smit, A., Boellaard, R., Kok, I. C., Oosting, S. F., Schröder, C. P., Hiltermann, T. J. N., van der Wekken, A. J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0255-8 · Cited by 732
Self-citationCurrent approaches to the management of brain metastases
Suh, J. H., Kotecha, R., Chao, S. T., Ahluwalia, M. S., Sahgal, A., & Chang, E. L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0320-3 · Cited by 553
ImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
Metadata
- Authors
- Dijkers, E. C., Oude Munnink, T. H., Kosterink, J. G., Brouwers, A. H., Jager, P. L., de Jong, J. R., van Dongen, G. A., Schröder, C. P., Lub-de Hooge, M. N., & de Vries, E. G.
- Venue
- Clinical Pharmacology & Therapeutics
- Publisher
- Wiley
- Published
- 2010-03-31
- Volume
- 87
- Issue
- 5
- Pages
- 586-592
- ISSN
- 0009-9236 (ISSN-L)
- 1532-6535
- OpenAlex
- W2122767481
- Cited by
- 805
- References
- 18
- FWCI
- 30.86
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.